Frontiers in endocrinology · 2026 · 統合分析（依標題推測）

Efficacy of intraovarian autologous platelet-rich plasma in women with poor ovarian reserve or ovarian insufficiency: a meta-analysis of randomized controlled trials.

女性運動員・RED-S · 卵巢功能不全

中文閱讀摘要

統合分析顯示卵巢內PRP可改善卵巢儲備指標但未提升妊娠率，因研究數少且異質性高，證據有限。

AI 依來源摘要整理，未經人工逐篇核對。閱讀結論前，請回溯研究族群、方法與限制。

原始摘要

Background

Poor ovarian reserve and ovarian insufficiency pose major challenges in reproductive medicine, with limited effective therapeutic options. Intraovarian autologous platelet-rich plasma (PRP) has shown potential benefits, but its efficacy remains uncertain based on current randomized controlled trials (RCTs).

Methods

This review followed PRISMA guidelines and was registered in PROSPERO (CRD420251233432). We systematically searched PubMed, Cochrane Central, Embase, CNKI, VIP, and Wanfang up to November 22, 2025, for randomized controlled trials of intraovarian autologous PRP in women with diminished ovarian reserve or ovarian insufficiency. Meta-analyses were performed using Stata 16, with heterogeneity assessed by the I² statistic. Risk of bias and study quality were evaluated using the Cochrane RoB 2 tool and the PEDro scale. Primary outcomes included serum anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), antral follicle count (AFC), and pregnancy rates.

Results

This meta-analysis included seven RCTs involving 422 women with poor ovarian reserve or ovarian insufficiency/failure. PRP treatment was associated with significant improvements in several ovarian reserve-related parameters: AFC increased (MD = 0.81, 95% CI 0.31 to 1.30; I² = 41.63%), AMH increased (SMD = 0.91, 95% CI 0.41 to 1.42; I² = 54.32%), FSH decreased (MD = -5.72, 95% CI -7.03 to -4.41; I² = 0.00%), and estradiol increased (MD = 26.03, 95% CI 19.53 to 32.53; I² = 0.22%). However, PRP treatment did not significantly improve pregnancy rates compared with controls.

Conclusions

This meta-analysis suggests that intraovarian PRP may improve ovarian reserve-related markers in women with poor ovarian reserve or ovarian insufficiency/failure, but it does not appear to increase pregnancy rates significantly. These findings should be interpreted cautiously because of the limited number of studies and heterogeneity in treatment protocols, and current evidence remains insufficient to define the optimal PRP regimen or the patient subgroups most likely to benefit.

Systematic review registration

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251233432, identifier CRD420251233432.

至 Europe PMC 閱讀完整來源 ↗ · 擷取日期 2026-10-19

書目、來源與全文狀態

DOI: 10.3389/fendo.2026.1827041
PMID／PMCID: 42205258 / PMC13201205
作者: Fang Y, Liu C, He Z, Zheng Y, Zhu L, Ye Z
首次發表日期: 2026-05-12Europe PMC 提供，部分日期可能依年份或月份推定。
卷／期／頁碼或文章編號: 17 ／期未提供／ 1827041
書目來源與查核日期: Europe PMC · 2026-10-19僅核對書目欄位與來源連結；不代表已評讀研究品質。
全文與授權: 來源列有免費全文（查核 2026-10-19），未逐篇測試 PDF 下載。來源授權標示：cc by。

可回溯引用

Fang Y, Liu C, He Z, Zheng Y, Zhu L, Ye Z. Efficacy of intraovarian autologous platelet-rich plasma in women with poor ovarian reserve or ovarian insufficiency: a meta-analysis of randomized controlled trials. Frontiers in endocrinology. 2026;17:1827041. PMID: 42205258. PMCID: PMC13201205. doi:10.3389/fendo.2026.1827041

原始文獻 ↗來源列出的免費全文 ↗

本站供教育與研究參考。單篇摘要、文體標籤與期刊影響係數不等於證據品質或個別病人的診療建議。